Peng Jing, Zhang Zhi-Chao
Department of Andrology， Peking University First Hospital， Beijing 100034， China.
Zhonghua Nan Ke Xue. 2023 Sep;29(9):771-775.
There is a close relationship between male erectile dysfunction (ED) and premature ejaculation (PE) on the pathogenesis, leading a high comorbidity rate and a need of simultaneous treatment in clinical practice. Phosphodiesterase 5 inhibitors (PDE5i) and selective serotonin reuptake inhibitor (SSRI) Dapoxetine are first-line oral drugs for ED and PE, respectively. In recent years, multi-country clinical guidelines have provided suggestions and guidance for the combination of these two drugs, with the safety and effectiveness being further explored and verified. This review summarized the status of ED and PE comorbidity, treatment principles, and research progress on the safety and effectiveness of Dapoxetine combined with PDE5i, in order to provide reference for the combination therapy of ED and PE comorbidity.
男性勃起功能障碍（ED）与早泄（PE）在发病机制上存在密切关系，导致临床实践中合并症发生率较高且需要同时治疗。磷酸二酯酶5抑制剂（PDE5i）和选择性5-羟色胺再摄取抑制剂（SSRI）达泊西汀分别是治疗ED和PE的一线口服药物。近年来，多国临床指南为这两种药物的联合应用提供了建议和指导，其安全性和有效性也在进一步探索和验证。本综述总结了ED与PE合并症的现状、治疗原则以及达泊西汀联合PDE5i安全性和有效性的研究进展，以便为ED与PE合并症的联合治疗提供参考。
